<DOC>
	<DOCNO>NCT00682383</DOCNO>
	<brief_summary>To determine safety efficacy administer filgrastim concurrent chemoradiotherapy potential benefit administer pegfilgrastim consolidation chemotherapy patient unresectable locally advanced NSCLC patient .</brief_summary>
	<brief_title>Combined Modality Therapy With Growth Factor Support Locally Advanced Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Histologically cytologically confirm NSCLC : Either histologic cytologic proof newly diagnose nonsmall cell lung cancer require . A biopsy histology prefer , cytology allow . Histology cytology involve mediastinal supraclavicular lymph node alone allow separate distal primary lesion clearly evident radiograph ( i.e. , second biopsy require ) . Patients two parenchymal lesion opposite side lung ineligible . Must unresectable Stage IIIA ( N2 ) IIIB disease also satisfy follow criterion : Unresectable Stage IIIA ( N2 ) patient : N2 mediastinal lymph node must multiple and/or bulky CT scan Xray , , opinion treat investigator , patient candidate induction chemotherapy chemoradiotherapy follow surgical resection . N2 status must document one follow method : Histologic cytologic proof N2 disease exploratory thoracotomy , thoracoscopy , mediastinoscopy , mediastinotomy , Wang needle biopsy , fine needle aspiration bronchoscopic CT guidance method Node positivity PET scan Nodes &gt; 2 cm CT scan Paralyzed leave true vocal cord separate leave lung primary distinct AP window node CT Scan Stage IIIB patient : Pathologic document radiographically document positive N3 node . Patients positive supraclavicular scalene lymph node must disease extend cervical region evidence one following : Fine needle aspiration , core needle biopsy excisional biopsy supraclavicular N3 node Biopsy contralateral mediastinal N3 node mediastinoscopy , mediastinotomy , thoracotomy Fine needle aspiration , core needle Wang needle biopsy CT bronchoscopic fluoroscopic guidance enlarge contralateral N3 mediastinal nod Contralateral mediastinal node &gt; 2 cm CT scan Contralateral node positivity PET scan Right side primary paralyzed leave true vocal cord Any follow T4 lesion : Tumor size invades follow : mediastinum , heart , great vessel , trachea , esophagus , vertebral body carina : Written documentation type T4 extent attend surgeon patient exploratory thoracotomy thoracoscopy T4 involvement trachea carina direct bronchoscopic visualization T4 involvement heart , esophagus , aorta , vertebral body document CT scan , MRI transesophageal ultrasound T4 involvement mediastinum may also accept CT MRI criterion , absence organ involvement , soft tissue extension directly mediastinal space . Radiographic criterion involvement main pulmonary artery vein allow mediastinal soft tissue mass . Age &gt; 18 year ECOG performance status 0 1 Ability give inform consent Adequate organ marrow function evidence follow peripheral blood count serum chemistry study entry : WBC &gt; 4,000/ÂµL Absolute neutrophil count &gt; 1,500/mm3 Platelet count &gt; 100 x 103 cells/mm3 Bilirubin &lt; 1.5 x institutional ULN AST ALT &lt; 2.5 x institutional ULN Alkaline Phosphatase &lt; 2.5 x institutional ULN Serum Creatinine &lt; 2.0mg/dL and/or adequate creatinine clearance Adequate pulmonary function ( FEV &gt; 1.5 liter , &lt; 1.5 liter , predict FEV1of contralateral lung must &gt; 800 cc base quantitative split function test . ( Predicted FEV1= FEV1 x % perfusion uninvolved lung quantitative lung V/Q scan report ) Must one measurable lesion chest Xray CT scan . Lesion ( ) must accurately measure least one dimension ( long diameter record ) &gt; 20mm conventional technique &gt; 10mm spiral CT scan Men woman childbearing potential must agree use effective contraception treatment 6 month treatment Malignant pleural pericardial effusion Prior chemotherapy radiation therapy Pregnant lactating female Primary malignancy basal squamous carcinoma skin carcinoma situ cervix , cancer patient disease free five year . Other situ malignancy ( e.g . breast , bladder , etc ) past 3 year permissible Unintentional weight loss &gt; 10 % body weight within last 3 month Unable provide inform consent Any premalignant myeloid condition malignancy myeloid characteristic Active infection Known hypersensitivity E. coliderived protein , pegfilgrastim , Filgrastim , component product Significant nonmalignant disease include : document HIV infection ; uncontrolled heart disease , poorly control diabetes Treatment within last 30 day experimental agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Advanced NSCLC</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Mount Sinai Medical Center CCOP</keyword>
</DOC>